THANK YOU FOR SUBSCRIBING
Quench Bio closes $50 million Series A financing round led by RA Capital Management
FREMONT, CA: Quench Bio closed its Series A round of financing led by RA Capital Management, collecting a total investment of $50 million. The company focuses on leveraging innovative insights into gasdermin biology and innate immunology to design medicines for severe inflammatory diseases. The funding round saw the participation of new investors, such as Abbvie Ventures. Atlas Venture, and Arix Bioscience plc, who have also co-founded and contributed for the seed fund of Quench Bio. Since its inception, Quench Bio is incubating at Atlas.
The team at Quench Bio is led by drug developers, scientists, and veterans with deep experience in inflammation and small molecule drug discovery. The company leads in the therapeutic approach centers that assist inhibition of Gasdermin D, which was recently termed as the key target at the core of multiple inflammatory cell death pathways, such as pyroptosis and NETosis. Under activation of pyroptosis or NETosis pathways, the process of gasdermin occurs, forming lytic pores on the cell membrane. This allows the release of inflammatory cytokines, alarmins, DNA, and NETs. Rheumatoid arthritis, lupus, multiple sclerosis and nonalcoholic steatohepatitis (NASH), and numerous other inflammatory diseases are associated with Pyroptosis and NETosis.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
"Targeting gasdermin provides a unique therapeutic opportunity, as there are currently no marketed therapies inhibiting inflammatory cell death," said Samantha Truex, CEO of Quench Bio. "Unlike approaches that target individual inflammasomes or cytokines, by targeting gasdermin, we aim to simultaneously inhibit multiple inflammatory cell death pathways that drive severe inflammatory diseases."
"We are excited about Quench Bio's first-in-class approach to potentially enable effective treatments for important autoimmune diseases with significant unmet medical need, and we look forward to supporting this exceptional team as they pioneer modulation of gasdermin biology, an important and promising novel target in inflammation," said Josh Resnick, M.D., Managing Director and co-head of Ventures at RA Capital, who will join the Quench Bio board as a new director alongside Adam Houghton, Head of AbbVie Ventures. Other board members include Samantha Truex as CEO, Bruce Booth of Atlas Venture, Jonathan Tobin of Arix Bioscience, Herbert Waldmann, Director at the Max Planck Institute and Jo Viney, President, CSO and Co-Founder of Pandion Therapeutics.
The company Quench Bio was launched in 2018 by Atlas, Arix, Mark Tebbe, Ph.D., Chief Technology Officer, and Mike Nolan, Ph.D., Head of Biology, along with Arturo Zychlinsky and Herbert Waldmann, Directors at The Max Planck Institute who partnered with the Lead Discovery Center on inhibitors of NETosis and gasdermin.
See also: Drug Discovery And Development Solutions Companies
More in News